摘要
目的探讨氨溴特罗结合孟鲁司特治疗小儿咳嗽变异性哮喘的临床作用及安全性。方法回顾性分析2011年2月到2012年12月濮阳市中原油田妇幼保健院接收的60例咳嗽变异性哮喘患儿的临床资料。结果氨溴特罗和孟鲁司特单一治疗患儿咳嗽改善情况无明显差异(P>0.05);但两种药物联合治疗咳嗽间隔时间明显延长,且咳嗽缓解率明显低于单一用药组(P<0.05)。结论患儿由于年龄小、抵抗力弱,长时间咳嗽容易发展成为咳嗽变异性哮喘,采取氨溴特罗联合孟鲁司特治疗可有效改善临床症状,且安全、有效。
Objective To investigate the clinical effect and safety of combination Ambroxol and clenbuterol montelukast in treatment of pediatric cough variant asthma. Methods A retrospective analysis in February 2011 to December 2012 in our hospital received CVA clinical data of 60 children. Results Ambroxol and montelukast in children with special single cough improvement was no significant difference（ P 〉 0. 05 ） , but the two drugs in combination therapy significantly prolonged interval of cough and cough remission rate was significantly lower than the monotherapy group（ P 〈 0. 05 ）. Conclusion Because younger children, weak resistance, easy to develop into a prolonged cough cough variant asthma, take ambroxol and clenbuterol joint montelukast therapy can effectively improve the clinical symptoms, and is safe and effective.
出处
《医药论坛杂志》
2015年第1期64-65,共2页
Journal of Medical Forum
